| abstract |
Disclosed are heparanase inhibiting compounds of general formula (I), wherein the substituents are as defined in the specification; in free form or in the form of pharmaceutically acceptable salts formed with a base or an acid as well as in the form of solvates or hydrates. The compounds are useful for the treatment of cardiovascular diseases such as atherosclerosis, post-angioplasty restenosis, diseases linked to complications which appear following the fitting of endovascular prostheses and/or aortocoronary bypass surgery or other vascular transplants, cardiac hypertrophy or vascular complications of diabetes such as diabetic retinopathy, chronic inflammatory diseases such as rheumatoid arthritis or inflammatory bowel disease, and macular degeneration. |